Dong H. Ma

Guangzhou, CN 
Guangzhou, CN 

Overview

Dong Ma practices practicing medicine in Guangzhou, China.

His clinical expertise encompasses Colorectal Cancer, Esophageal Cancer, Hemolysis, Autosomal Recessive Hypotrichosis, and Osteotomy.

He is actively involved in clinical research, co-authoring 97 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

Guangzhou, 510080, China
Other Locations
Dongguan Key Laboratory Of Central Nervous System Injury And Repair, Dongguan, 523573, China
Capital Medical University & Beijing Key Laboratory Of Fundamental Research On Biomechanics In Clinical Application, Beijing, China
Guangdong Provincial Key Laboratory Of Materials And Technologies For Energy Conversion, Shantou, 515063, China
Anhui Province Key Laboratory Of Pollutant Sensitive Materials And Environmental Remediation, Huaibei, 235000, China
China
Hefei, 230031, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 3

97 Total Publications

Macrophages diverge into profibrotic SAMs and proresolving ReM2 cells to regulate liver fibrosis.
Macrophages diverge into profibrotic SAMs and proresolving ReM2 cells to regulate liver fibrosis.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: August 21, 2026

Frequently Asked Questions about Dong H. Ma

Is Dong H. Ma a top-rated expert for Osteotomy?

MediFind is an objective health platform that identifies experts based on real-world data. Dong H. Ma is classified as an Experienced expert for Osteotomy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Dong H. Ma participate in research or clinical trials?

Yes. Dong H. Ma has published 97 articles and abstracts on conditions like Osteotomy. You can view a list of Dong H. Ma's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ma's expertise for a condition
ConditionClose
        View All 13 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile